The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Putilina M.V.

Kafedra nevrologii fakulteta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Ermoshkina N.Iu.

Kafedra nevrologii FUV GOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet", Moskva

Sigitov I.S.

Pirogov Russian National Research Medical University, Moscow, Russia

Sidelnikova L.V.

Filatov City Clinical Hospital №15, Moscow, Russia

Progressive multifocal encephalopathy in neurological practice

Authors:

Putilina M.V., Ermoshkina N.Iu., Sigitov I.S., Sidelnikova L.V.

More about the authors

Read: 15353 times


To cite this article:

Putilina MV, Ermoshkina NIu, Sigitov IS, Sidelnikova LV. Progressive multifocal encephalopathy in neurological practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12):95‑105. (In Russ.)
https://doi.org/10.17116/jnevro201711712195-105

References:

  1. Bag АK, Curé JK, Chapman PR, Roberson GH. JC-virus infection of the brain. Neuroradiol. 2010;31(9):1564-1576. https://doi.org/10.3174/ajnr.A2035
  2. Weissert R. Progressive multifokale Leukenzephalopathie. Journal of Neuroimmunologie. 2011;231:73-74.
  3. Belov BS. Progressive multifocal leukoencephalopathy: Rheumatological aspects. Sovremennaya Revmatologiya. 2015;9(3):4-9. (In Russ.) https://doi.org/10.14412/1996-7012-2015-3-4-9
  4. Engsig FN, Hansen AB, Omland LH. Incidence, Clinical Presentation and outcome of progressive multifocal leukoencephalopathy in HIV infected patients during the highly active antiretroviral therapy era: A Nationwide Cohort Study. Infect. J Infect Dis. 2009;199(1):77-83. https://doi.org/10.1086/595299
  5. Power C, Gladden JG, Haliday W. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology. 2000;54:743-746.
  6. Falconi M. Novartis Gilenya patient gets rare brain disease. The Wall Street Journal. 2012. http://online.wsj.com/article/SB10001424052702304444604577341490361751420.html
  7. Kobayashi K, Okamoto Y, Inoue H Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med. 2009;48(15):1307-1309. https://doi.org/10.2169/internalmedi-cine.48.1926
  8. Berger JR. The clinical features of PML. Cleve Clin J Med. 2011;78:8-12.
  9. Tan SK, Koralnik I. JC, BK and otherpolyomaviruses: Progressive multifocal leu-coencephalopathy. In: Bennet JE, Dolin R,Blaser MJ, editors. Mandel, Douglas and Bennet’s principles and practice of infectious diseases, 8th ed. New York: Saunders; 2015.
  10. Zakarova MN. Progressive multifocal leukoencephalopathy (review). Journal of Neurology and Psychiatry im. S.S. Korsakova. 2012;112(9):2:29-33. (In Russ.)
  11. Berger J, Aksamit A, Clifford D. PML diagnostic criteria: Consensus statement from the AAN. Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438. https://doi.org/10.1212/wnl.0b013e31828c2fa1
  12. Lima MA, Marzocchetti A, Autissier P. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. Virol. 2007;81:3361-3368.
  13. Vinhas de Souza M, Keller-Stanislawski B, Blake K Drug-induced PML: a global agenda for a global challenge. Clin Pharmacol Ther. 2012;91(4):747-750.
  14. Davidovsky MV, Kochanova N V, Evdoshenko EP, Pronin IN, Boyko A N, Alifirova VM, Turova EA, Malkova NA, Sivertseva SA. Cukurova LA, Skoromets AA, Solodun IYu. Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. Zhurnal nevrologii I psikhiatri im. S.S. Korsakova. 2016;116(10):79-97. (In Russ.) https://doi.org/10.17116/jnevro20161161027997
  15. Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, Martinez M, Verbanaz SC, Salazar ZS, Pardal MF, Reisin R. Immune reconstruction inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurol. 2006;67:1692-1694. PMID: 17101910
  16. Wysowski D, Bozic C. Natalizumab’s Risk Minimization action plan and risk management plan. Food and Drug administration’s peripheral and central nervous system drug advisory committee meeting. Gaithersburg MD; 2006.
  17. Bennett CL, Nebeker JR, Yarnold PR. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007;167:1041-1049.
  18. Calabrese LH, Molloy E, Berger J. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol. 2015;11(2):119-123. (In Russ.) https://doi.org/10.1038/nrrheum.2014.167
  19. Steiner I, Berger JR. Update on progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep. 2012;12(6):680-686. https://doi.org/10.1007/s11910-012-0313-4
  20. Breton S. The Cellular Physiology of Carbonic Anhydrases. J Pancreas (Online). 2001;2(4):159-164.
  21. Putilina MV. Patient comorbidity in clinical practice. Consilium Medicum. 2017;19(2):71-79. (In Russ.)
  22. Pinelis VG, Storozhevykh TP, Surin AM, Senilova YaE, Persiyantzeva NF, Tukhmatova GR, Andreeva LA, Myasoedov NF, Granstrem O. Neuroprotective effects of cortagen, cortexin and semax on glutamate neurotoxicity. J PeptideScience. 2008;14(8):159-160.
  23. Adriani W, Granstrem O, Romano E. Modulatory effects of cortexin and cortagen on locomotor activity and anxiety-related behavior in mice. Open Neuropsychopharmacology Journal. 2009;2:22-29.
  24. Yakovlev AA, Gulyaeva NV. Molecular Partners of Cortexin in the Brain. Neirokhimiya. 2017;34(1): 91-96. (In Russ.) https://doi.org/10.1134/S1819712416040164
  25. Adibhatla RM, Hatcher JF. Cytidine 5’-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005;30:15-23.
  26. Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299:188-192.
  27. Putilina MV. Combined therapy of cerebrovascular disorders with neuroprotectors. Journal of Neurology and Psychiatry im. S.S. Korsakova. 2016;116(11):57-62. (In Russ.)
  28. Ye J, Lin H, Mu J, Cui X, Ying H, Lin M, Wu L, Weng J, Lin X. Effect of basic fibroblast growth factor on hippocampal cholinergic neurons in a rodent model of ischaemic encephalopathy. Basic & Clinical Pharmacology & Toxicology. 2010;107:931-939. https://doi.org/10.1111/j.1742-7843.2010.00603.x
  29. Secades H. Tsitikolin: pharmacological and clinical review, updating 2010. Rev Neurol. 2011; 52(2):1-62. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.